EAM Global Investors’s Akero Therapeutics AKRO Stock Holding History

EAM Global Investors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-33,509	Closed	-$1.84M	–	89
2022 Q4	$1.84M	Sell	33,509 -22,051	-40%	-$945K	0.47%	95
2022 Q3	$1.89M	Buy	+55,560	New	+$850K	0.5%	81
2020 Q4	–	Sell	-49,718	Closed	-$1.53M	–	132
2020 Q3	$1.53M	Buy	+49,718	New	+$1.74M	0.56%	88

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Global Investors's AKRO Position: Q1 2023 in Review

EAM Global Investors sold out of Akero Therapeutics (AKRO) in Q1 2023, closing a stake of 33,509 shares — an estimated $1.84M sold.

EAM Global Investors first reported a position in AKRO in Q3 2020 and held it in 3 quarters. The position peaked at $1.89M in Q3 2022. 156 funds tracked by Wall St. Rank hold AKRO as of Q1 2023.

EAM Global Investors reported no remaining Akero Therapeutics position as of Q1 2023 after selling out during the quarter.
EAM Global Investors sold 33,509 Akero Therapeutics shares in Q1 2023, an estimated $1.84M.
EAM Global Investors first reported a position in Akero Therapeutics in Q3 2020 and held it in 3 quarters.
EAM Global Investors's Akero Therapeutics position peaked at $1.89M in Q3 2022.
156 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.